Letter to the Editor: Midodrine for Hepatic Hydrothorax
- PMID: 32772399
- DOI: 10.1002/hep.31513
Letter to the Editor: Midodrine for Hepatic Hydrothorax
Comment in
-
Reply.Hepatology. 2021 Mar;73(3):1237-1238. doi: 10.1002/hep.31512. Epub 2021 Feb 26. Hepatology. 2021. PMID: 32767857 No abstract available.
Comment on
-
Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.Hepatology. 2020 Nov;72(5):1851-1863. doi: 10.1002/hep.31434. Epub 2020 Oct 22. Hepatology. 2020. PMID: 32585037 Review. No abstract available.
References
-
- Banini BA, Alwatari Y, Stovall M, Ogden N, Gershman E, Shah RD, et al. Multidisciplinary management of hepatic hydrothorax in 2020: an evidence‐based review and guidance. Hepatology 2020 Jun 25. https://doi.org/10.1002/hep.31434 . [Epub ahead of print] - DOI
-
- Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore) 2014;93:135‐142.
-
- Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012;56:348‐354.
-
- Kulkarni AV, Kumar P, Singh S, Sharma M, Talukdar R, Murthy VHV, et al. Prevention of paracentesis‐induced circulatory dysfunction—a systematic review and network meta‐analysis. GastroHep 2020;2:92‐101.
-
- Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck‐Radosavljevic M, et al. Alfapump ® system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study. J Hepatol 2017;67:940‐949.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
